From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA approval expands access to factor Xa inhibitor antidote Andexxa

from Monthly Prescribing Reference

Portola announced that the Food and Drug Administration has approved the Prior Approval Supplement for its second generation Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo) for full commercial launch in the U.S., expanding patient access. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063